Therefore, BCR-ABL is a good therapeutic target for CML against which various inhibitors, such as imatinib, nilotinib, bosutinib, and ponatinib, have been developed. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.